De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CorMedix Beheer

Beheer criteriumcontroles 3/4

De CEO CorMedix's is Joe Todisco, benoemd in May2022, heeft een ambtstermijn van 2.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.46M, bestaande uit 25.1% salaris en 74.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.27% van de aandelen van het bedrijf, ter waarde $ 1.22M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 2.6 jaar.

Belangrijke informatie

Joe Todisco

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris	25.1%
Dienstverband CEO	2.4yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09

CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

Feb 11

We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Jan 04

Analyse CEO-vergoeding

Hoe is Joe Todisco's beloning veranderd ten opzichte van CorMedix's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$53m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$2m	US$617k	-US$46m
Sep 30 2023	n/a	n/a	-US$40m
Jun 30 2023	n/a	n/a	-US$37m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$3m	US$378k	-US$30m

Compensatie versus markt: De totale vergoeding ($USD 2.46M ) Joe } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Joe is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Joe Todisco (47 yo)

2.4yrs

Tenure

US$2,459,432

Compensatie

Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022. He has served as Director of CorMedix Inc. since March 18, 2022 and served as its Independ...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Todisco	CEO & Director	2.4yrs	US$2.46m	0.27% $ 1.3m
Matthew David	Executive VP & CFO	4.4yrs	US$1.03m	0.019% $ 92.9k
Erin Mistry	Executive VP & Chief Commercial Officer	4.6yrs	US$1.26m	0.023% $ 115.8k
Elizabeth Masson-Hurlburt	Executive VP and Chief Clinical Strategy & Operations Officer	less than a year	US$844.81k	0.014% $ 70.3k
Kaufman Zelnick	Executive VP	less than a year	geen gegevens	geen gegevens
Donna Ucci	Senior VP & Head of Global Quality	2.4yrs	geen gegevens	geen gegevens
Tushar Mukherjee	Senior VP & Head of Technical Operations	1.8yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

44.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CRMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Todisco	CEO & Director	2.6yrs	US$2.46m	0.27% $ 1.3m
Myron Kaplan	Independent Chairman of the Board	8.5yrs	US$191.96k	0.32% $ 1.6m
Alan Dunton	Independent Director	5.6yrs	US$141.42k	0.027% $ 135.7k
Janet Dillione	Independent Director	9.2yrs	US$147.42k	0.096% $ 475.9k
Steven Lefkowitz	Independent Director	7.3yrs	US$162.42k	0.14% $ 689.8k
Gregory Duncan	Independent Director	3.9yrs	US$141.42k	0% $ 0
Bruce Polsky	Member of Scientific Advisor Board	no data	geen gegevens	geen gegevens
Saravanan Balamuthusamy	Member of Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens
Sara Bonnes	Member of Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens
Aru Narendran	Member of Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens
Hannah Newman	Member of Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens
Jonathan Waitman	Member of Scientific Advisory Board	2.5yrs	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CRMD wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

CorMedix Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CEO & Director recently bought US$51k worth of stock

CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts

CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023

CorMedix Inc., Annual General Meeting, Oct 26, 2023

Cormedix Inc. Announces Resignation of Paulo F. Costa as Member of the Board of Directors, Effective as of October 15, 2023

Cormedix Inc. Announces Promotions in Commercial and Tech Ops

Recent updates

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

CorMedix Inc. to Report Q2, 2024 Results on Aug 14, 2024

CorMedix Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

CorMedix Inc. to Report Q1, 2024 Results on May 09, 2024

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)

New minor risk - Share price stability

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

CEO & Director recently bought US$51k worth of stock

Forecast breakeven date moved forward to 2025

CorMedix Inc. to Report Q4, 2023 Results on Mar 12, 2024

Price target decreased by 7.0% to US$13.25

CorMedix Inc. Updates Related to Its Business and Anticipated Launch of DefenCath

Cormedix Inc. Announces Commercial and Operational Updates

Forecast to breakeven in 2026

CorMedix Inc. Approves the Separation of Employment of Phoebe Mounts

CorMedix Inc. Announces the Appointment of Beth Zelnick Kaufman, Esq. as Executive Vice President, Chief Legal Officer, and Corporate Secretary, Effective December 12, 2023

CorMedix Inc. Announces FDA Approval of DefenCath(R) to Reduce the Incidence of Catheter Related Bloodstream Infections in Adult Hemodialysis Patients

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2022)

CorMedix Inc. to Report Q3, 2023 Results on Nov 14, 2023

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

CorMedix Inc., Annual General Meeting, Oct 26, 2023

Cormedix Inc. Announces Resignation of Paulo F. Costa as Member of the Board of Directors, Effective as of October 15, 2023

Price target decreased by 18% to US$13.75

First half 2023 earnings released: US$0.49 loss per share (vs US$0.38 loss in 1H 2022)

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc. to Report Q2, 2023 Results on Aug 08, 2023

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

Cormedix Inc. Announces Resubmission of New Drug Application for Defencath

First quarter 2023 earnings released: US$0.24 loss per share (vs US$0.18 loss in 1Q 2022)

CorMedix Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Cormedix Inc. Announces Promotions in Commercial and Tech Ops

CEO & Director recently bought US$76k worth of stock

Price target increased to US$15.00

High number of new and inexperienced directors

Price target increased to US$15.00

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.23 loss in 3Q 2021)

CorMedix Inc. to Report Q3, 2022 Results on Nov 10, 2022

CorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference

CorMedix Inc., Annual General Meeting, Oct 13, 2022

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.12 loss in 2Q 2021)

Consensus forecasts updated

CorMedix Inc. Announces Regulatory and Manufacturing Updates

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

CorMedix Inc. to Report Q2, 2022 Results on Aug 11, 2022

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc.(NasdaqGM:CRMD) dropped from Russell 2000 Dynamic Index

High number of new and inexperienced directors

Consensus forecasts updated

No longer forecast to breakeven

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CorMedix Inc. Announces Executive Changes

CorMedix Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Price target decreased to US$22.00

No longer forecast to breakeven

CorMedix Inc. Announces Formation of New Scientific Advisory Board

Consensus forecasts updated

No longer forecast to breakeven

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

Cormedix Inc. Resubmits the New Drug Application for DefenCath to Address the Complete Response Letter Issued by the U.S. Food and Drug Administration

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Independent Chairman of the Board recently bought US$51k worth of stock

Third quarter 2021 earnings released: US$0.23 loss per share (vs US$0.22 loss in 3Q 2020)

Price target decreased to US$22.00

CEO & Director Khoso Baluch has left the company

Executive Vice President for Technical Operations John Armstrong has left the company

Pomerantz Law Firm Announces the Filing of A Class Action Against CorMedix Inc. and Certain Officers